Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases

ABSTRACT

The invention relates to pharmacology and medicine, in particular to a class of mitochondrially-addressed compounds which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases and diseases and pathological conditions caused by disturbed blood circulation or oxygen supply to tissues and organs.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/667,061, entitled “Use of Mitochondrially-Addressed Compounds for Preventing and Treating Cardiovascular Diseases,” which was filed Nov. 17, 2010, which is a U.S. national phase under 35 U.S.C. §371 of International Patent Application No. PCT/RU2007/000355, filed Jun. 29, 2007, the entire disclosures of each of which are incorporated by reference herein.

FIELD OF THE INVENTION

The invention relates to pharmacology and medicine, in particular to a class of chemical compounds of structure (I) which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases as well as diseases and pathological conditions caused by disorders of blood circulation or oxygen supply to tissues and organs.

BACKGROUND OF THE INVENTION

In today's world, cardiovascular diseases are the leading cause of death (29% of all deaths in 2002 (The world health report 2004)): hypertension and stroke (one of its most severe complications), atherosclerosis, ischemic brain disease (which is in most cases caused by atherosclerosis), and finally, ischemic heart disease and acute myocardial infarction (as its manifestation).

In a broad sense, infarction implies necrosis of part of organ due to insufficiency of blood supply, or mechanical or bacterial/viral lesions. Usually, infarction is a consequence of ischemia—the situation in which a lumen-bearing blood vessel becomes narrowed due to atherosclerotic plaque, or a vessel becomes obstructed by a thrombus or compressed by any entity (e.g., cyst or tumor). According to WHO estimates, ischemic heart disease and its consequences resulted in 12.6% of deaths in 2002 (The world health report 2004). In industrialized countries, this proportion is even higher—30%.

Anti-ischemic measures include several interrelated stages: prevention of ischemia or its treatment and prevention of its most severe consequences, such as infarction. The prevention includes reduction of risk factors, primarily atherosclerosis development: smoking cessation, reduction the level of low density lipoproteins (LDL) in the blood, diet, lifestyle, etc. In the development of ischemia, the primary goal is to restore blood supply (reperfusion) of tissue within 1.5-2 hours after onset of ischemia, and for that purpose, vasodilators (e.g., nitroglycerin), anticoagulants (aspirin, heparin), thrombolytic agents, beta-adrenergic blockers relieving stress and reducing oxygen demand in ischemic tissue, oxygen therapy, and finally, surgical methods, such as angioplasty, bypass surgery, etc. are used.

Reperfusion of tissue, especially after long-term ischemia, is accompanied by the accumulation of reactive oxygen species (ROS) (J. L. Zweier, J. T. Flaherty, M. L. Weisfeldt. Direct measurement of free radical generation following reperfusion of ischemic myocardium. 1987, PNAS USA, 84, 1404-1407). During ischemia, the partial pressure of oxygen in cells decreases, electron carriers of the mitochondrial respiratory chain are reduced that leads to enhanced generation of reactive oxygen species (superoxide anion radical at first, then hydrogen peroxide), accompanied by transition of iron atoms from the ferric state (Fe³⁺) to the ferrous states (Fe²⁺). This facilitates the Fenton reaction, thus generating a powerful oxidant, the OH* radical. Neutrophils attracted to the ischemic focus also actively release superoxide and hydrogen peroxide on the background of increased oxygen delivery during reperfusion.

All this leads to the activation of free-radical oxidation (A. J. Tompkins, L. S. Burwell, S. B. Digemess, C. Zaragoza, W. L. Holman and P. S. Brookes. Mitochondrial dysfunction in cardiac ischemia-reperfusion injury: ROS from complex I, without inhibition. 2006, Biochim Biophys Acta. 1762, 2, 223-231), and as a consequence, the development of oxidative stress. The latter leads to consequences which are often more severe than ischemic blood circulatory disorders per se (Vanden Hoek T L, Shao Z, Li C, Zak R, Schumacker P T, Becker L B. Reperfusion injury in cardiac myocytes after simulated ischemia. 1996, Am. J. Phys., 270, 1334-1341). Free radicals have a direct damaging effect on intracellular protein structures, nucleic acids, as well as various membranes; peroxidation of polyunsaturated fatty acids embedded in the membranes, in turn, disturbs the. barrier properties of the membranes and leads to perturbed ion homeostasis (in the case of reperfused heart muscle, lipid peroxidation and the peroxidation-induced ion imbalance are considered as one of the leading causes of reperfusion cardiac arrhythmias). In addition, free radical compounds initiate vasoconstriction and hyper-coagulability, and accelerated degradation of NO which mediates vasorelaxant (in this situation—anti-ischemic) action.

Namely ROS are considered to be one of the key factors triggering the mechanism of necrosis and apoptosis in ischemic tissue. Therefore, preventing the synthesis of mitochondrial ROS or neutralization of the latter is crucial for survival or recovery of the function of ischemic tissue cells.

Attempts to reduce reperfusion-induced oxidative stress in ischemic tissue were made repeatedly. For example, local hypoxia—reduction of perfusate oxygen content entering the ischemic heart during the first few minutes of reperfusion, suppressed ROS generation and had a protective effect on mitochondria (G. Petrosillo, N. Di Venosa, F. M. Ruggiero, M. Pistolese, D. D'Agostino, E. Tiravanti, T. Fiore, G. Paradies. Mitochondrial dysfunction associated with cardiac ischemia/reperfusion can be attenuated by oxygen tension control. Role of oxygen-free radicals and cardiolipin. 2005, Biochimica et Biophysica Acta, 1710, 78-86).

When ischemic tissue is subjected to hypothermic conditions, ROS production is also reduced, the consequences of ischemia are mitigated, thereby increasing time period during which the tissue can remain under ischemic condition without irreversible changes during the subsequent reperfusion (Riess M. L., Camara A. K. S., Kevin L. G., An J., Stowe D. F. Reduced reactive O₂ species formation and preserved mitochondrial NADH and [Ca²⁺] levels during short-term 17° C. ischemia in intact hearts. 2004, Cardiovascular Research, 61, 580-590). A positive clinical effect of hypothermia was also observed (Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest, 2002, New Engl. J. Med., 346, 8, 549-56). However, the clinical applicability of the said method—as well as said local hypoxia—is very limited, primarily because of technical difficulties.

Another way to mitigate the damage caused by ischemia and reperfusion is the use of chelating agents binding free ferrous iron; accumulation of Fe²⁺ ions in ischemic tissue is one of the factors stimulating a surge in ROS synthesis during reperfusion (the Fenton reaction which occurs with hydroxyl radical formation).

It was shown that the use of chelating agents inhibits ROS synthesis during reperfusion (Spencer K T, Lindower P D, Buettner G R, Kerber R E. Transition metal chelators reduce directly measured myocardial free radical production during reperfusion. 1998, J. Cardiovasc Pharmacol, 32, 3, 343-348), reduces infarct size (C. Demougeot, M. Van Hoecke, N. Bertrand, A. Prigent-Tessier, C. Mossiat, A. Beley, and C. Marie. Cytoprotective Efficacy and Mechanisms of the Liposoluble Iron Chelator 2,2-Dipyridyl in the Rat Photothrombotic Ischemic Stroke Model. 2004, The Journal of Pharmacology and Experimental Therapeutics, 311, 1080-1087). However, it should be noted that the clinical use of chelating agents is limited since they can cause side effects: for example, long-term use of iron ion chelator such as deferoxamine (especially by young people) can lead to stunted growth, speech disorder, hearing loss, disorder of skeletal formation ((Faa G., Crisponi G. Iron chelating agents in clinical practice. 1999, Coordination Chemistry Reviews, 184, 1, 291-310), heart malfunction and hypotension (Kirschner R E, Fantini G A. Role of iron oxygen-derived free radicals in ischemia-reperfusion injury. 1994b J. Am. Coll. Surg., 179, 103-117).

Finally—since the case in point is ROS-induced damage—it would be logical to assume that preparations with antioxidant effect may also reduce the risk of myocardial infarction and to mitigate the severity of other adverse effects in ischemic tissue. Indeed, it was shown (Kutala VK, Khan M, Mandal R., Potaraju V., Colantuono G., Kumbala D, Kuppusamy P. Prevention of Postischemic Myocardial Reperfusion Injury by the Combined Treatment of NCX-4016 and Tempol. 2006, J Cardiovasc Pharmacol., 48, 3, 79-87), that pre-perfusion of rat heart with antioxidant Tempol reduced infarct size caused by subsequent ischemia/reperfusion by 1.5 times, and the combination of Tempol and NCX-4016 (NO donor)—by almost 2 times. Reduction of ROS production and protection of membrane lipids in ischemic heart mitochondria from peroxidation by means of antioxidant melatonin was demonstrated by Petrosillo et al. (Petrosillo G, Di Venosa N, Pistolese M, Casanova G, Tiravanti E, Colantuono G, Federici A, Paradies G, Ruggiero F. M. Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemiareperfusion: role of cardiolipin. 2006, The FASEB Journal, 20, 269-276).

At the same time, attempts to achieve the effect of preventing the development of ischemic processes by means of specialized vitamins-antioxidants (vitamins C, E and beta-carotene), failed to reveal clinical relevance of such prevention (Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. 2004, Lancet, 363, 9411, 757-767). In a review (Kromhout D. Diet and cardiovascular diseases. 2001, J. Nutr. Health Aging, 5, 144-149) on the same issue, similar conclusions were made: convincing clinical evidence for the ability of antioxidants, vitamins E and C as well as carotenoides, to prevent the development of ischemic heart disease was not obtained.

The apparent contradiction between the encouraging results of the experiments on cell cultures or isolated organs, on the one hand, and the disappointing clinical trial data—on the other hand, may be partly explained by “the problem of delivery”. Antioxidant therapy should be conducted at the beginning of reperfusion, the start time of which, in turn, is critical to prevent or minimize the development of myocardial infarction. Antioxidant must not only be promptly delivered to the ischemic region—its intracellular localization is also important. It is possible that namely the inability of existing antioxidant preparations to be quickly and selectively transported into mitochondria, the ROS generation site, is the cause of the low efficiency of such preparations in clinical practice (Becker L. B. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. 2004, Cardiovascular Research, 61, 461-470).

For delivery of antioxidants to mitochondria, a strategy with two different mechanisms of its implementation can be applied. The strategy is based on transport of a required antioxidant to mitochondria which is conjugated with elements transported to the mitochondrial matrix. The nature of these elements is twofold—these can be either penetrating lipophilic cations which can be spontaneously transported along the electric field created on the inner mitochondrial membrane, or signal peptide sequences being part of the transported peptides, after their processing the mature protein is brought into the correct mitochondrial compartment.

To date, very limited number of biologically active compounds is known which can be targeted to mitochondria at the expense of energy of electrochemical potential of hydrogen ions. Among these are mitochondria-targeted antioxidant MitoQ and its variants (MitoQ5, MitoQ3). The said substances are ubiquinol (the reduced form of ubiquinone) attached to triphenylphosphonium through C-10 linker group (C-5, C-3, respectively). In description of the invention U.S. Pat. No. 6,331,532, MitoQ is claimed to be an active compound of compositions intended for the treatment and prevention of diseases associated with oxidative stress. Another compound, mitochondria-targeted mimetic of glutathione peroxidase ebselen is claimed in the claims of invention U.S. Pat. No. 7,109,189 as treatment for adverse effects of reperfusion of ischemic tissue, infarction and as preparation applicable in surgery and transplantation. However, the authors of said invention did not provide any experimental data supporting the possibility of such use of ebselen, since data on the antioxidant properties of ebselen were obtained in experiments on isolated mitochondria and mitochondrial membranes.

A work (Adlam V J, Harrison J C, Porteous C M, James A M, Smith R A, Murphy M P, Sammut I A. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury 2005, FASEB J., 19, 1088-1095) shows an example of the effect of MitoQ observed in an experiment where rats were fed the said compound for 14 days, with subsequent study of the properties of their isolated hearts perfused by Langendorfs method and exposed to ischemia/reperfusion. Said data indirectly confirm the statement that MitoQ can be used for prevention or treatment of ischemic myocardial damage. However, normothermal ischemia followed by reperfusion used by the authors of the said work has all the limitations of in vitro model. Also, given the apparent lack of reliable statistics to assess the number of experiments (6 animals in each group), it remains unclear how much do the average values obtained characterize the changes in the restoration of cardiac function associated with the chemical structure of antioxidants, rather than differences in the development of arrhythmias.

Summarizing this section, one can conclude that at present there is no clinically applicable and experimentally confirmed scheme of treatment and prevention of heart diseases by means of mitochondria-targeted antioxidants.

DESCRIPTION OF THE INVENTION

One aspect of the present invention is a new application of a pharmaceutical composition of mitochondria-targeted antioxidants (i.e., compounds of structure (I)) to produce medicinal preparations that are intended for the prevention and treatment of cardiovascular pathologies, as well as diseases and pathological conditions originating from disorders of blood circulation or oxygen supply to tissues and organs.

Said composition comprises compounds that include targeting moiety, linker group and antioxidant, and the general chemical structure of these compounds can be described by the following structure (I):

wherein:

-   -   A is an effector/antioxidant moiety:

and/or reduced form thereof, wherein:

-   -   m is an integer from 1 to 3;     -   each Y is independently selected from the group consisting of a         lower alkyl, a lower alkoxy; or two adjacent Y groups, together         with carbon atoms to which they are attached, form the following         structure:

-   -   and/or reduced form thereof, wherein:         -   R1 and R2 may be the same or different and are each             independently a lower alkyl or a lower alkoxy;     -   L is a linker group, comprising:         -   a) a straight or branched hydrocarbon chain which can be             optionally substituted by one or more substituents and             optionally contains one or more double or triple bonds; or         -   b) a natural isoprene chain;     -   n is an integer from 1 to 20;     -   B is a targeting group comprising Sk⁺Z⁻, wherein:         -   Sk⁺ is a lipophilic cation; and         -   Z is a pharmacologically acceptable anion;     -   with the proviso that in compound of structure (I) A is not         ubiquinone (e.g.         2-methyl-4,5-dimethoxy-3,6-dioxo-1,4-cyclohexadienyl), or         tocopherol or a mimetic of superoxide dismutase or ebselen;         while L is a divalent decyl or divalent pentyl or divalent         propyl radical; and while B is triphenylphosphonium cation;

or solvates, isomers, prodrugs, or pharmacologically acceptable salts thereof.

Another aspect of the present invention is the use of a pharmaceutical composition for manufacturing medicinal preparations that are intended for the prevention and treatment of cardiovascular pathologies, including atherosclerosis, cardiac arrhythmias, ischemic heart disease, cardiac infarction, renal ischemia or infarction, stroke, as well as diseases and pathological conditions originating from disorders of blood circulation or oxygen supply to tissues and organs.

One more aspect of the present invention is the use of a pharmaceutical composition for treatment of pathological conditions that are consequences of nonischemic blood circulation disorders, including the consequences of hemorrhagic hypovolemia caused by destruction of vessels or violation of their permeability as well as hypovolemia caused by vasodilators.

Another aspect of the present invention is the use of a pharmaceutical composition for treatment of pathological conditions that are consequences of nonischemic blood circulation disorders, including hypovolemia caused by loss of water through the skin, lungs, gastrointestinal tract or kidneys, including hypovolemia provoked by diuretics.

One more aspect of the present invention is the use of a pharmaceutical composition for treatment of consequences of hypoxic hypoxia caused by a lack of oxygen in arterial blood, including hypoxia caused by a lack of oxygen in inhaled air.

Another aspect of the present invention is the use of a pharmaceutical composition for treatment of consequences of anemic hypoxia caused by decrease in oxygen capacity of blood due to a fall in hemoglobin content or change in its state.

One more aspect of the present invention is the use of a pharmaceutical composition for the prevention or treatment of unwanted changes in cells, tissues or organs in which natural blood circulation and oxygen supply are limited or terminated during medical intervention, including apheresis, reducing or eliminating blood supply to cells, tissues or organs to the purpose of their further conservation and/or transplantation as well as various surgical operations.

Ischemic heart disease is considered to mean: angina pectoris, unstable angina, unstable angina with hypertension, angina pectoris with documented spasm, angina pectoris with documented spasm with hypertension, acute myocardial infarction, acute transmural anterior wall myocardial infarction, acute transmural anterior wall myocardial infarction with hypertension, acute transmural inferior wall myocardial infarction, acute transmural inferior wall myocardial infarction with hypertension, acute subendocardial myocardial infarction, acute subendocardial myocardial infarction with hypertension, myocardial reinfarction, inferior wall myocardial reinfarction, some current complications of acute myocardial infarction, and hemopericardium as complication following acute myocardial infarction, atrial septal defect as current complication of acute myocardial infarction, ventricular septal defect as current complication of acute myocardial infarction, atrial thrombosis, auricular thrombosis and ventricular thrombosis as current complications of acute myocardial infarction, other forms of acute ischemic heart disease, coronary thrombosis which does not lead to myocardial infarction, Dressler's syndrome, Dressler's syndrome with hypertension, chronic ischemic heart disease, atherosclerotic cardiovascular disease, previous experience of myocardial infarction, cardiac aneurysm, cardiac aneurysm with hypertension, coronary artery aneurysm, coronary artery aneurysm with hypertension, ischemic cardiomyopathy, asymptomatic myocardial ischemia.

Other heart diseases are considered to mean: acute pericarditis, acute nonspecific idiopathic pericarditis, infectious pericarditis, chronic adhesive pericarditis, chronic constrictive pericarditis, non-inflammatory pericardial effusion, acute and subacute endocarditis, acute and subacute infective endocarditis, non-rheumatic mitral valve lesions, mitral valve insufficiency, mitral valve prolapse, non-rheumatic mitral valve stenosis, non-rheumatic aortic valve lesions, aortic valve stenosis, aortic valve insufficiency, non-rheumatic tricuspid valve lesions, non-rheumatic tricuspid valve stenosis, non-rheumatic tricuspid valve insufficiency, pulmonary valve lesions, pulmonary valve stenosis, pulmonary valve insufficiency, pulmonary valve stenosis with insufficiency, acute myocarditis, infectious myocarditis, isolated myocarditis, cardiomyopathy, dilated cardiomyopathy, hypertrophic obstructive cardiomyopathy, endomyocardial (eosinophilic) disease, endocardial fibroelastosis, alcoholic cardiomyopathy, cardiomyopathy caused by medicinal agents and other external factors, atrioventricular block and left His' bundle block, first-degree atrioventricular block, second-degree atrioventricular block, complete atrioventricular block, preexcitation syndrome, cardiac arrest, cardiac arrest with successful restoration of cardiac activity, paroxysmal tachycardia, recurrent ventricular arrhythmia, supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, premature atrial depolarization, premature ventricular depolarization, sick sinus syndrome, heart failure, congestive heart failure, left ventricular failure, myocardial degeneration.

Stroke is considered to mean hemorrhagic stroke, ischemic stroke, and their symptoms.

Renal ischemia or renal infarction is considered to mean: periarteritis nodosa, Wegener's granulomatosis, hemolytic-uremic syndrome, idiopathic thrombocytopenic purpura, disseminated intravascular coagulation syndrome (DIC syndrome), renal artery ischemia, or renal artery infarction (extrarenal part), renal arteriosclerosis, congenital renal stenosis, Goldblatt kidney, acute nephritic syndrome, minor glomerular disorders, focal and segmental glomerular lesions, diffuse membranous glomerulonephritis, diffuse mesangial proliferative glomerulonephritis, diffuse endocapillary proliferative glomerulonephritis, diffuse mesangiocapillary glomerulonephritis, rhabdomyolysis, dense deposit disease, diffuse crescentic glomerulonephritis, rapidly progressive nephritic syndrome, recurrent and persistent hematuria, chronic nephritic syndrome, nephrotic syndrome, nephritic syndrome.

Application of pharmaceutical compositions related to the present invention can be both somatic and local. Procedures of administration comprise enteral, such as oral, sublingual and rectal; local, such as transdermal, intradermal and oculodermal; and parenteral. Suitable parenteral procedures of administration comprise injections, for example, intravenous, intramuscular, subdermal, intraperitoneal, intraarterial, and other injections, and non-injecting practices, such as vaginal or nasal, as well as procedure of administration of a pharmaceutical composition in form of angioplastic stent coating. Preferably, compounds and pharmaceutical compositions related to the present invention are for intraperitoneal, intravenous, intraarterial, parenteral or oral administration. In particular, administration can be given in form of injections or tablets, granules, capsules or other pressed or compressed form.

When a compound of structure (I) is administered as a pharmaceutical composition, a compound of structure (I) should be mixed according to formula with a suitable amount of pharmacologically acceptable solvent or carrier so that to have the appropriate form for administration to a patient. The term “solvent” relates to diluent, auxiliary medicinal substance, filler or carrier which is mixed with a compound of structure (I) for administration to a patient. Liquids like water, and oils including petrolic, animal, vegetative and synthetic, such as peanut oil, soybean oil, mineral oil and other similar oils can be used as said pharmacological carriers. Normal saline solution, acacia pitch, gelatin, starch, talc, keratin, colloid silver, urea etc can serve as said pharmacological solvents.

Said composition can also include auxiliary substances, stabilizers, thickeners, lubricant and coloring agents.

Compounds and compositions related to the present invention can be administered in form of capsules, tablets, pills, pillets, granules, syrups, elixirs, solutions, suspensions, emulsions, suppositories or retarded release substances, or in any other form suitable for administration to a patient. One aspect of the present invention is application of compounds of structure (I) and compositions in form of solutions for oral, intraperitoneal, intraarterial and intravenous administration.

Therapeutically justified amount of a compound of structure (I) required for treatment of a specific disease or symptom, depends on the nature of disease or symptom and a procedure of administration and should be determined at consultation with a physician in charge. Acceptable doses for oral administration are from 0.025 to 120000 microgram per kg of patient body weight, 25 microgram per kg of patient body weight is more preferable, and 50 microgram per kg of patient body weight is the most preferable. Acceptable doses for intravenous administration are from 0.1 to 10000 microgram per kg of patient body weight, 25 microgram per kg of patient body weight is more preferable, and 125 microgram per kg of patient body weight is the most preferable.

For optimal protection of cells, tissues and organs, a compound of structure (I) in form of a pharmaceutical composition is administered 6-48 hours (optimally—24 hours) prior to ischemic exposure.

Examples of Acceptable Pharmaceutical Compositions for Oral Administration Pharmaceutical Composition-1—Gelatin Capsules:

Ingredient Amount (mg/capsule) Compound of structure (I) 0.0015-1000    Starch 0-650 Starch powder 0-650 Liquid silicone 0-15 

Pharmaceutical Composition-2—Tablets:

Ingredient Amount (mg/capsule) Compound of structure (I) 0.0015-1000   Microcrystalline cellulose 200-650  Silicon dioxide powder 10-650 Stearic acid 5-15

Pharmaceutical Composition-3—Tablets:

Ingredient Amount (mg/capsule) Compound of structure (I) 0.0015-1000 Starch 45 Microcrystalline cellulose 35 Polyvinylpyrrolidone (10% aqueous solution) 4 Carboxymethylcellulose, sodium salt 4.5 Talc 1 Magnesium stearate 0.5

Pharmaceutical Composition-4—Suspensions:

Ingredient Amount (mg/5 ml) Compound of structure (I) 0.0015-1000 Syrup 1.25 Benzoic acid solution 0.10 Carboxymethylcellulose, sodium salt 50    Flavoring By necessity Coloring By necessity Distilled water Up to 5 ml An example of acceptable pharmaceutical composition in the form of solution for intraperitoneal, intraarterial and intravenous administration (pH 6.5):

Ingredient Amount Compound of structure (I)   5 mg Isotonic solution 1000 ml An example of acceptable pharmaceutical composition for administration in the form of aerosol:

Ingredient Amount (weight percent) Compound of structure (I) 0.0025 Ethanol 25.75 Difluorochloromethane 70 An example of acceptable pharmaceutical composition for administration in the form of suppositories:

Ingredient Amount (mg/suppository) Compound of structure (I) 1 Glycerides of saturated fatty acids 2000

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the effect of preparation SkQ1 on myocardial infarction size caused by ischemia followed by reperfusion of Wistar rat hearts.

FIG. 2 shows the effect of SkQ1 on H₂O₂-induced development of arrhythmias in isolated hearts of Wistar rats.

FIG. 3 shows the influence of SkQR1 on the survival of rats after ischemia in a single kidney.

FIG. 4 shows the antioxidant activity of SkQR1 in intact and ischemic kidney.

FIG. 5 shows the effect of SkQR1 on biochemical parameters of blood in rats with a single kidney after 90 minutes of ischemia.

FIG. 6 shows the effect of SkQR1 on functional parameters (the amount of urine release, glomerular filtration rate) of a single kidney after 90 minutes of ischemia.

FIG. 7 shows the effect of the preparation on behavioral disorders caused by cerebral compression ischemia in Wistar rats (test “open field”).

FIG. 8 shows the effect of the preparation on the lesion volume during cerebral compression ischemia in Wistar rats.

The following non-limiting Examples illustrate the preparation and use of compounds of structure I but should not be understood as limiting the invention as modifications in materials and methods will be apparent to the skilled person. The following examples should not be construed as limiting the scope of this disclosure.

These examples show that the correct use of compositions based on compounds of structure (I) can prevent or decelerate the development of pathological processes associated with ischemic blood circulation disorders in various organs including heart, kidney and brain.

Examples

1. Reduction of Myocardial Infarction Size in Rats after Regional Ischemia and Reperfusion in the Presence of SkQ1

To study a possibility of reduction of the irreversible damage of cardiomyocytes by SkQ1 in vivo a model of regional myocardial ischemia and reperfusion in anesthetized rats was used. Experiments were performed on Wistar male rats weighing 300-450 grams, fed a standard diet. In the control animals during three weeks received NaBr dissolved in 0.1 M phosphate buffer (pH 6.0), at a dose of 250 nmol/kg body weight/day. Animals of the experimental group during three weeks together with food received SkQ1 dissolved in 0.1 M phosphate buffer (pH 6.0), at a dose of 250 nmol/kg body weight/day.

In urethane-anesthetized animals (130 mg/kg body weight intraperitoneally administered), artificial ventilation of the lungs with room air with added oxygen at a rate of 60-80 beats per minute was carried out. Indicators of the acid-base balance of arterial blood (pH, pO₂ and pCO₂) during the entire experiment were controlled with the use of acid-base gas analyzer ABL-30 (Radiometer) and maintained at a physiological level.

Catheterization of the carotid artery was performed for recording arterial pressure (Mingograf 804, Siemens-Elema). The chest was opened by longitudinal dissection of the sternum and the heart was freed from the pericardium. To induce regional myocardial ischemia, the left ventricle was pierced with an atraumatic needle 5-0 under the left appendage in the direction perpendicular to long axis of the heart. Tightening the ligature at the anterior descending coronary artery (ADA) located deep in the pierced myocardium ceased blood supply to a portion of the myocardium, weakening of the ligature restored coronary flow.

The dissection is followed by a 30-min period of stabilization of hemodynamic parameters (the initial state). Then anterior descending coronary artery was occluded for 40 min followed by 60 min of reperfusion. At the end of the experiment, to identify the risk zone (RZ) and the intact zone, anterior descending coronary artery was occluded and a 2% Evans solution (2 ml) was injected as a bolus into the jugular vein. Then the heart was cut out and the left ventricle (LV) was separated and frozen at −20° C.

To measure infarct size, the method for histochemical localization of the risk zone (RZ) and myocardial infarction (MI) by tissue staining with 2,3,5-triphenyltetrazolium chloride (TFT) was used (Kitakaze M., Takashima S., Funaya H., Minamino T., Node K., Shinozaki Y., Mori H., Hori M., 1997. Temporary acidosis during reperfusion limits myocardial infarct size. Am. J. Physiol.; 272: H2071-H207). Cross-sections with a thickness of about 1.5-2 mm were prepared from the left ventricle, which are then incubated for 10 min in 1% TFT solution in 0.1 M phosphate buffer (pH 7.4 at 37° C.). The obtained samples were scanned, MI and RZ sizes were determined by the method of computer-assisted planimetry using the Imagecal program. Then the sections were weighed to determine LV mass. In each group, the risk zone/weight of the left ventricle (RZ/LV) and the myocardial infarction/risk zone (MI/RZ) ratios were estimated (Pisarenko O. I., Studneva I. M., Serebriakova L. I., Tskitishvili O. V., Timoshin A. A. Protection of rat heart myocardium with a selective Na⁺/H⁺ exchange inhibitor and ischemic preconditioning. Kardiologiia (in Russian). 2005; 45 (2): 37-44).

It was shown that in the initial state the mean arterial blood pressure (BP) in all groups tested was 98+/−5 mm Hg. Art., heart rate (HR)—223+/−6 beats/sec. No effect of SkQ1 on blood pressure and heart rate was observed in the experimental group.

Histochemical analysis of the sections of the myocardium after reperfusion revealed no differences with regard to RZ/LV (%) between the groups. This indicated that damage to the coronary basin that supplies the left ventricle was identical in both groups. At the same time, in the group of animals received SkQ1, MI/RZ ratio was reliably 1.7 times less as compared to the control (P<0.005) (FIG. 1).

Thus, SkQ1 at a dose of 250 nmol/kg body weight/day exhibits cardioprotective properties—limits the size of experimental myocardial infarction in rats in situ reliably reducing ischemic and reperfusion injury of the heart.

2. The Effect of SkQ1 on H₂O₂-Induced Development of Arrhythmias in Isolated Rat Hearts

Wistar rats received preparation SkQ1 daily for 3 weeks at doses of 2.0, 0.2 and 0.02 nmol/kg body weight by its addition to the curd. In the control group of animals, the feed was supplemented with sodium bromate in a similar dose. Experiments on isolated hearts were performed 1-2 days after the end of administration of the preparations by a standard technique under conditions of retrograde perfusion of the heart with a controlled rate of perfusion and a measurement of spontaneous heart rate. The effect of SkQ1 on the incidence of arrhythmias induced by injection of hydrogen peroxide (100 μm) into the coronary bed of hearts was studied. This model reproduces some features of a situation of oxidative stress that develops during reperfusion of ischemic heart.

Injection of hydrogen peroxide into the coronary bed of hearts of the control series by the 25^(th)-40^(th) minute was accompanied with the development of bradycardia and arrhythmia in most experiments, so that a sustainable heart rate persisted in only 26% of the experiments (FIG. 2). Automatism in hearts of rats received SkQ1 at doses of 0.02, 0.2 and 2.0 nmol/kg was more resistant to H₂O₂— the normal rhythm was maintained in 55, 70 and 58% of the experiments, respectively. The number of experiments in the control group and in the group received SkQ1 at a dose of 0.2 nmol/kg was the same—23, and the normal rhythm was documented in 6 control hearts and in 16 hearts from the group received SkQ1.

Thus, SkQ1 in the model system reduces the development of arrhythmias which develop during oxidative stress.

3. The Influence of SkQR1 on the Survival of Rats after Ischemia in a Single Kidney

The survival of rats in which one kidney was removed and the second kidney was subjected to ischemia was studied. With ischemia in a single kidney, crisis occurs quite rapidly (2 days after ischemia), largely resulting in animal death. At the same time, with ischemia in one kidney, another kidney remains intact, and nothing fatal to the organism happens (apparently the intact kidney starts to perform double work).

In experiments on survival, rats were intraperitoneally injected with SkQR1 (SkQ1 derivative) in saline at a dosage of 1 μm 1 day before surgery, the final injection volume was 5 ml.

One day after the injection of the compound, the rats were laparotomized, the kidney and its vascular pedicle (renal artery and vein) were isolated, the kidney was separated from surrounding tissues to avoid lateral blood flow. Ischemia was performed on the left kidney, the right kidney remained intact or was removed. Ischemia was created by clamping the renal vascular pedicle with a clamp. Lack of blood flow in the kidney was monitored visually judging from a change in color of kidney tissue. Duration of ischemia varied from 60 to 90 minutes. After a period of ischemia, the clamps were removed and blood flowing into the kidney starts again, that moment was taken as the onset of reperfusion. An animal was put stitches, antiseptic on its wound and the anesthesia was stopped. The urine and blood samples were taken from the rats.

The distinct protective effect of SkQR1 on survival of rats in which a single kidney was subjected to ischemia/reperfusion was shown (FIG. 3). Normalization of a number of blood biochemical parameters (the creatinine and urea contents (FIG. 5)) and improvement in kidney function (glomerular filtration rate, the amount of urine release (FIG. 6)) in ischemic rats received SkQR1 were also observed.

4. The Antioxidant Activity of SkQR1 in Intact and Ischemic Kidney

Wistar rats divided into four groups were used in the experiment:

Group 1—intact rats were injected with preparation SkQR1 at a dose of 1 μmol/kg and after 1 day the production of reactive oxygen species was monitored judging from the intensity of the fluorescent probe 2′,7′-dichlorofluorescein (DCF) in sections of the intact kidney.

Group 2—Study of production of reactive oxygen species in sections of the intact kidney without injection of Rh-SkQR1.

Group 3—prior intraperitoneal injection of Rh-SkQ in rats at a dose of 1 μmol/kg 1 day before the 40-minute ischemia of the kidney.

Group 4—40-minute ischemia of the kidney without injection of the preparation (control 2).

Wistar rats from groups 1 and 3 were intraperitoneally injected with 1 μmol/kg SkQR1 per day. Rats from groups 3 and 4 were subjected to heat ischemia of the left kidney by clamping the renal vessels for 40 minutes. Then, in the ischemic kidney, blood flow was restored for 10 minutes, after that the kidney was removed, the cortex was used to prepare thin sections with a thickness of 150-200 microns, the sections were incubated at 25° C. for 10 minutes in the incubation medium containing 10 mM 2′,7′-dichlorofluorescein diacetate ether which is a fluorescent probe detecting reactive oxygen species, and fluorescence in renal tubules was investigated with the use of confocal laser microscope LSM 510 (Carl Zeiss, Germany). Fluorescence was excited by an argon laser at 488 nm with the fluorescence emission at 505-530 nm. For quantitative analysis of fluorescence intensity of dyes, confocal images of the kidney sections at zoom of .times.10 and standardized microscope settings (laser excitation intensity, the extent of program signal amplification etc.) were obtained. The fluorescence intensity was evaluated using a 255-point scale, the area of zones with high fluorescence intensities (above 50 units) and the specific ratio of these areas to total fluorescence area were estimated.

The results showed (FIG. 4) that in intact rats, the fluorescence intensity of DCF in the kidney sections after injection of SkQR1 at a dose of 1 μmol/kg decreased from 11 to 4 relative units of fluorescence intensity as compared to the kidneys of rats which did not receive the preparation that indicates a high antioxidant activity of Rh-SkQ.

After 40 minutes of ischemia and 10 minutes of reperfusion, the formation of reactive oxygen species by mitochondria of renal tubules increased almost 3 times. At the same time, in the experiments with prior injection of SkQR1, the formation of reactive oxygen species in the kidney after 40 minutes of ischemia and 10 minutes of reperfusion remained at a low level comparable with normal values.

These results suggest that SkQR1 effectively suppresses the excess generation of reactive oxygen species in renal tubule epithelial cells, thereby providing the kidney with the effective protection against ischemic injury.

5. The Effect of SkQR1 on Behavioral Disorders Caused by Brain Hemorrhagic Stroke in Rats

Neurobiological studies were performed on Wistar rats weighing from 150 to 220 g with the use of a model of brain hemorrhagic stroke induced by artificial compression ischemia. This model reproduces some features of a situation that develops during hemorrhagic stroke when blood flow presses on the brain leading to ischemia and subsequent atrophy of an area of the brain.

One day before surgery, rats were intraperitoneally injected with SkQR1 in saline at a dosage of 1 μm, the final injection volume was 5 ml. Before surgery, rats were intraperitoneally injected with 3% solution of chloral hydrate at a dose of 350 mg/kg. The head of the anesthetized animal was fixed in the stereotactic device.

After fixation, the hair was shaved off from the head skin and a median longitudinal incision was made. At the place to be trepanned (over the parietal or frontal lobes of the cerebral cortex), the periosteum was separated. Using a cylindrical cutter with a diameter of 5 mm, trepanations were made in the parietal region of the animal skull departing 1 mm from the median suture. In order to avoid a thermocoagulation effect, the surface of the skull was cooled with saline during drilling. Dura mater was excised without damaging the brain surface.

To induce compression ischemia, Teflon rod was used which was inserted through the guiding glass tube into trepanations. Rod pressure on the brain surface was 40 mm Hg. Art. Compression of the cortex lasted for 15 minutes, then the rod was removed, the wound was treated with dry potassium salt of penicillin, the skin was sewn up and the suture was treated with 2% iodine solution.

During 6 days after ischemia, the behavior of the experimental animals (4 animals had ischemia only and 5 animals had ischemia and SkQR1 treatment) was studied using the test “open field”.

The first test was performed before administration of SkQR1 to animals, the second test was performed 24 hours after administration, just before ischemia. Based on the first test, the rats were divided into two groups approximately equal with respect to behavior and weight. The second test showed that intraperitoneal injection of SkQR1 had no noticeable effect on behavior of rats for one day (FIG. 7). The third and fourth tests showed a noticeable difference in behavior between treated and untreated animals. Increased horizontal and vertical activity of the untreated animals, as compared to the treated animals, indicates an increase in their emotional tension, anxiety (FIG. 7).

According to the literature, if rats pass the test “open field” for a few days, results with each subsequent test should be lower as compared to the previous one due to habituation of rats to a new environment. Rats administered SkQR1 revealed virtually the same behavior (FIG. 7) whereas a clear violation of that rule was found in the control individuals, also pointing to increased anxiety in untreated ischemic rats and indirectly to dysfunction in elements of their memory.

Thus, SkQR1 reduces the development of behavioral abnormalities caused by cerebral compression ischemia.

6. The Effect of SkQR1 on the Degree of Development of Brain Hemorrhagic Stroke in Rats

On the seventh day of said experiment, neuromorphological analysis of the brain in the experimental animals was conducted using a model of brain hemorrhagic stroke. For neurohistological analysis, the experimental animals anesthetized with chloral hydrate were subjected to transcardiac perfusion using a modified Tellenitskii fixative, i.e., a mixture of formalin, alcohol, and acetic acid at a ratio of 2:7:1 (FAAC). Then the brain was extracted and paraffinated by a standard histological method and cut into sections with a thickness of 20 microns with a microtome. The paraffin sections were stained by the Nissl method. The sections were scanned and analyzed using the ImagJ program. The true value for the lesion volume was estimated using the Excel program.

Under control conditions without pre-treatment with SkQR1, a significant brain damaged area adjacent to part of the brain directly affected by compression was observed. The lesion extends deep into the brain and the lesion volume can serve as an estimate of the degree of damage. The data of external examination of the rat brain demonstrate a clear trend to reduce the size and intensity of hemorrhagic focal lesions in the animals received SkQR1 prior to ischemia. Data for statistical analysis showed that the average size of the ischemic focus in animals which did not receive SkQR1 was 7.6 mm³, whereas in animals received SkQR1—0.9 mm³. (FIG. 8).

The results of said experiments suggest that SkQR1 is able to reduce the focus of brain hemorrhagic stroke. 

1. (canceled)
 2. (canceled)
 3. A pharmaceutical antioxidant formulation comprising about 740 ng/g to about 9.3 mg/g SkQ1 having the structure:

and its reduced form SkQ1H2:

wherein Z⁻ is a pharmacologically acceptable anion.
 4. (canceled)
 5. A pharmaceutical antioxidant formulation comprising about 6.0 μg/g to about 7.5 mg/g SkQ3 having the structure:

and its reduced form SkQ3H2:

wherein Z⁻ is a pharmacologically acceptable anion. 6.-36. (canceled)
 37. A pharmaceutical antioxidant formulation comprising about 740 ng/g to 9.3 mg/g SkQ1 in pill, capsule, or suppository form, or about 740 ng/ml to 9.3 mg/ml SkQ1 in liquid intravenous or oral form, having the structure:

and its reduced form SkQ1H2:

wherein Z⁻ is a pharmacologically acceptable anion.
 38. A pharmaceutical antioxidant formulation for oral administration, comprising about 1.5 μg/g to about 3 mg/g SkQ having the structure:

wherein: A is the effector/antioxidant moiety:

and/or reduced form thereof, wherein: m is an integer from 1 to 3; and each Y is methyl; L is a linker group, comprising: a) a straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds; or b) a natural isoprene chain; n is an integer from 1 to 20; and B is a targeting group comprising Sk⁺Z⁻, wherein: Sk⁺ is a lipophilic cation; and Z⁻ is a pharmacologically acceptable anion; and a pharmaceutically acceptable carrier thereof.
 39. A pharmaceutical antioxidant formulation for intravenous administration, comprising about 6.0 μg/ml to about 7.5 mg/ml SkQ having the structure:

wherein: A is the effector/antioxidant moiety:

and/or reduced form thereof, wherein: m is an integer from 1 to 3; and each Y is methyl; L is a linker group, comprising: a) a straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds; or b) a natural isoprene chain; n is an integer from 1 to 20; and B is a targeting group comprising Sk⁺Z⁻, wherein: Sk⁺ is a lipophilic cation; and Z⁻ is a pharmacologically acceptable anion; and a pharmaceutically acceptable carrier thereof. 